ClinicalTrialsFinder

Well-Differentiated Neuroendocrine Carcinoma Clinical Trials in San Francisco, California

1 recruitingSan Francisco, California

Showing 1–1 of 1 trials

Recruiting
Phase 2

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Neuroendocrine TumorsWell-Differentiated Neuroendocrine CarcinomaHigh Grade Neuroendocrine Carcinoma, Any Site
University of California, San Francisco29 enrolled1 locationNCT05746208